The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms
- Study type
- Clinical guideline
- Study name
- WHO-HAEM5 (Myeloid and Histiocytic/Dendritic)
- Design
- World Health Organization diagnostic classification (summary of the new classification scheme and the principles and rationale of the changes from the previous edition); not a clinical trial
- Sample size
- None (classification article; no patients enrolled)
- Source
- Leukemia · 2022
In plain words
The World Health Organization updates the list and definitions of blood cancers so that doctors everywhere use a common language. This article explains the group of myeloid blood cancers (such as some types of leukaemia) and histiocytic/dendritic diseases in the new classification. In this classification, besides how the disease looks under the microscope and its clinical features, more attention is paid to genetic features and markers that can help in choosing treatment or predicting the course of the disease. This article does not introduce a new treatment; under this classification, the name and way of diagnosing your disease may be written differently in new reports than in the past.
Key guideline recommendations
- Level of evidence not stated in the abstract
Disease types continue to be defined and diagnosed using multiple clinicopathological parameters, with refined diagnostic criteria and an emphasis on therapeutically and/or prognostically actionable biomarkers.
- Level of evidence not stated in the abstract
Where possible, diseases are defined on a genetic basis, while practical applicability worldwide is also taken into account.
Study population
This article did not enrol patients. Its subject is the classification of myeloid and histiocytic/dendritic neoplasms in the fifth edition of the World Health Organization classification of haematolymphoid tumours.
Endpoints
The article has no clinical endpoint. Its aim is to summarise the new WHO classification scheme for myeloid and histiocytic/dendritic neoplasms and to present the principles and rationale of the changes from the previous edition.
Safety and side effects
According to the abstract, safety is not addressed in this article, because no therapeutic intervention was studied.
Clinical significance and place in guidelines
According to the abstract, this classification updates the definition and diagnosis of myeloid and histiocytic/dendritic neoplasms with refined diagnostic criteria and an emphasis on therapeutically and/or prognostically actionable biomarkers, and is grounded in molecular biology. The abstract gives no information on its effect on specific treatment guidelines or regulatory drug approvals; its adoption in clinical guidelines and how it is applied at each centre should be checked separately.
Limitations
This record is based only on the abstract of the article. The exact list of disease types, the diagnostic criteria and the detailed changes from the previous edition are not in the abstract, and the full text should be consulted. The level of evidence and strength of recommendation for this classification are not reported in the abstract.
This summary was prepared by the editorial team from the published paper; the original paper is the final reference. Read the original abstract on PubMed.